CTOs on the Move

RareMed

www.raremed.com

 
RareMed Solutions offers comprehensive support services for specialty, orphan and ultra-orphan products. Our team has a breadth of experience developing and maintaining therapy specific solutions to ensure compliance. RareMed Solutions is the ideal partner for biotech firms and pharmaceutical manufacturers due to our custom solutions that are unique to each of our partner’s needs. RareMed Solutions is committed to providing the highest level of care to patients we serve. We offer specialized, highly-customizable services designed to increase patient access, affordability, and adherence to therapy. The extensive experience and unmatched service delivery translates to the best possible care for ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.raremed.com
  • 305 Merchant Lane
    Pittsburgh, PA USA 15205
  • Phone: 833.676.7273

Executives

Name Title Contact Details
Dennis Whalen
Vice President of Technology and Chief Technology Officer Profile

Similar Companies

Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients` needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sizewise

We offer bariatric and non-bariatric medical equipment including bed frames, therapeutic mattresses, and mobility items for patients of all ages.

Gandara Center

Gándara was established in 1977 by a doctor named Jose Gándara, of Puerto Rican descent who sought to provide mental health services to the growing and largely Hispanic community in Holyoke, Massachusetts. Recently the Gándara Center expanded services ...

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.